Distinctive clinical characteristics of malignant mesothelioma in young patients
- PMID: 26202904
- PMCID: PMC4599306
- DOI: 10.18632/oncotarget.4414
Distinctive clinical characteristics of malignant mesothelioma in young patients
Abstract
Although considered a disease of the elderly, a subset of patients with mesothelioma are young (<40 years). The goal of this study was to understand their characteristics and outcomes. The Surveillance, Epidemiology, and End Results (SEER) database was used to extract mesothelioma cases (1990-2010). We modeled Kaplan-Meyer survival curves stratified by site of disease, and age of presentation. 2% (207 of 12345) of mesothelioma patients are young. Sex distribution is comparable among the young (51% males, 49% females); males predominated (78%, 22%) in the older cohort. Frequency of pleural and peritoneal mesothelioma are similar in the young (47%, 48% respectively); pleural disease predominated in the old (90%, 9%). Cancer-directed surgeries are more frequent in the young. Regardless of histologic subtype, young patients with pleural (11 vs. 8 months) and peritoneal (not reached vs. 10 months) mesothelioma had significantly improved overall survival. In multivariate analysis, younger age was an independent prognostic factor. Although rare, mesothelioma do occur in the young; their characteristics are distinct from those of older patients. Further studies are needed to understand the interplay between genetic susceptibility and mineral fiber carcinogenesis in the pathogenesis of mesothelioma in the young.
Keywords: SEER analysis; asbestos; incidence among the young; mesothelioma.
Conflict of interest statement
None of the authors have potential conflicts of interest.
Figures
Similar articles
-
Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.Thorac Cancer. 2019 May;10(5):1193-1202. doi: 10.1111/1759-7714.13063. Epub 2019 Apr 5. Thorac Cancer. 2019. PMID: 30951250 Free PMC article.
-
[Malignant pleural mesothelioma].Ugeskr Laeger. 2018 Apr 9;180(15):V06170439. Ugeskr Laeger. 2018. PMID: 29690982 Review. Danish.
-
Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.J Formos Med Assoc. 2019 Jan;118(1 Pt 3):463-470. doi: 10.1016/j.jfma.2018.07.013. Epub 2018 Jul 31. J Formos Med Assoc. 2019. PMID: 30072200
-
Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.J Surg Oncol. 2023 Jul;128(1):134-141. doi: 10.1002/jso.27243. Epub 2023 Mar 18. J Surg Oncol. 2023. PMID: 36932968
-
Mesothelioma epidemiology, carcinogenesis, and pathogenesis.Curr Treat Options Oncol. 2008 Jun;9(2-3):147-57. doi: 10.1007/s11864-008-0067-z. Epub 2008 Aug 15. Curr Treat Options Oncol. 2008. PMID: 18709470 Free PMC article. Review.
Cited by
-
Association between Asbestos Exposure and the Incidence of Kidney Cancer: a Weight-of-Evidence Evaluation and Meta-analysis.Curr Environ Health Rep. 2023 Dec;10(4):394-409. doi: 10.1007/s40572-023-00415-6. Curr Environ Health Rep. 2023. PMID: 37889448 Review.
-
Development of a prognostic nomogram for patients with malignant mesothelioma with bone metastasis.Sci Rep. 2023 Jul 4;13(1):10789. doi: 10.1038/s41598-023-37679-9. Sci Rep. 2023. PMID: 37402761 Free PMC article.
-
The Association between the Histological Subtypes of Mesothelioma and Asbestos Exposure Characteristics.Int J Environ Res Public Health. 2022 Nov 5;19(21):14520. doi: 10.3390/ijerph192114520. Int J Environ Res Public Health. 2022. PMID: 36361401 Free PMC article.
-
Retrospective analysis of mesothelioma cases in a tertiary hospital in Northern Portugal (1988-2023): An epidemiological perspective.Porto Biomed J. 2025 Aug 5;10(4):e298. doi: 10.1097/j.pbj.0000000000000298. eCollection 2025 Sep-Oct. Porto Biomed J. 2025. PMID: 40766963 Free PMC article.
-
Molecular characterization of diffuse malignant peritoneal mesothelioma.Mod Pathol. 2020 Nov;33(11):2269-2279. doi: 10.1038/s41379-020-0588-y. Epub 2020 Jun 5. Mod Pathol. 2020. PMID: 32504035
References
-
- Rodriguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99:51–57. - PubMed
-
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644. - PubMed
-
- Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–46. - PubMed
-
- Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–218. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical